Institutional members access full text with Ovid®

Share this article on:

Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients

Ventriglio, Antonioa,d; Vincenti, Alessiob,c,d; Centorrino, Francad,e; Talamo, Alessandrab,c,d; Fitzmaurice, Garrette; Baldessarini, Ross J.d,e

International Clinical Psychopharmacology: March 2011 - Volume 26 - Issue 2 - p 88–95
doi: 10.1097/YIC.0b013e328340c0de
Original Articles

Treatments given to patients with primary psychotic disorders include mood stabilizers (MSs) combined with other psychotropics, despite the limited evidence of efficacy, safety, and lack of regulatory approval. We analyzed records of 636 inpatients at the McLean Hospital (2002–2009), who were diagnosed with bipolar disorder (n=318), a schizoaffective disorder (n=210), or schizophrenia (n=108), to evaluate MS-usage, drug-selections, combinations and doses, improvement, adverse-effect risks, associated factors, and secular trends. Between 2002 and 2009, the use of MSs increased from 53 to 94% of patients, MSs per patient increased by 74%, and the total final doses (lithium-equivalents in milligrams/day) increased by 35%. The most commonly prescribed MSs ranked: valproate, lithium, lamtogrine. With the use of MSs, the duration of hospitalization was longer by an average of 18%, Clinical Global Impression ratings improved by 55%, and adverse-effects risk was lower by 22%. In multivariate logistic modeling, treatment with a MS was associated with: (i) most recent year of sampling, (ii) more psychotropics per patient at discharge, (iii) diagnosis (schizophrenia < schizoaffective or bipolar disorders), (iv) longer period of hospitalization, and (v) somewhat younger age. MSs, usually in combination with antipsychotics, were used increasingly for inpatients over the past decade, including for patients with primary psychotic disorders. The effectiveness and safety of this practice remain to be evaluated adequately.

aDepartment of Psychiatry, University of Foggia, Foggia

bDepartment of Neurosciences, Mental Health, and Sensory Functions (NESMOS), Second Medical School, Sapienza University of Rome

cUnit of Psychiatry, Sant'Andrea Hospital, Rome, Italy

dInternational Consortium for Bipolar and Psychotic Disorders Research, McLean Division of Massachusetts General Hospital

eDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA

Correspondence to Dr Antonio Ventriglio, MD, University of Foggia, Institute of Psychiatry, Via Guglielmo Marconi No 3, 71041 Carapelle, Foggia, Italy Tel: +393 39 646 6525; fax: +1 617 855 3479; e-mail: a.ventriglio@libero.it

Received February 27, 2010

Accepted September 21, 2010

© 2011 Lippincott Williams & Wilkins, Inc.